|
K
M
R
S
e
r
v
i
c
e
s
|
|
|
|
KMR focuses on the pharmaceutical and
biotechnology companies. The services it offers are based on accumulated data
from over 4200 clinical studies conducted by more than 25 pharmaceutical
companies and numerous CROs. The data is continuously enriched as new studies
are added to the TrialMetrix database.
|
|
|
|
| |
Using its proprietary database,
TrialMetrix, KMR offers a cutting-edge method for companies to measure their
processes and performance against their competitors. Our benchmarking methods
encompass quantitative measures such as cycle time, quality and cost indicators
as well as qualitative measures.
|
| |
|
| |
All analyses are confidential. KMR
assesses how a company performs relative to the industry without revealing any
data corresponding with a specific company. All data KMR receives from its
clients is kept confidential.
|
| |
|
| |
|
|
|
| |
Clients concerned with optimizing
resources can take advantage of KMR's resource management model. KMR uses
activity-based process analysis to determine changing workload and resource
requirements across the entire range of R&D. This enables clients to
effectively evaluate their resource management strategies and determine when
they need to outsource or recruit.
|
| |
Another focus is clinical resource management. We have
a user friendly resource model that gives managers a powerful tool to project
and assess resource needs. It is a flexible application, permitting company
planners to run scenarios, adjusting for programs/studies that, for example,
are outsourced, do not start on time, or may not begin at all. It portrays
results in a variety of ways: by function or role, protocol, program, and
period or a combination of those. |
| |
|
| |
|
|
|
| |
KMR has compiled detailed enrollment
information from thousands of recent protocols conducted globally in all
indications. Clients are able to access this information, obtaining a powerful
tool to help them more efficiently manage and predict enrollment for specific
studies, as well as at more strategic levels where large-scale planning occurs
and performance is measured. Depending on the criteria selected, for each
protocol the outputs include: subject volume, site volume, subjects per site,
subjects per month, length of enrollment, enrollment curves. |
| |
|
| |
|
|
|
| |
KMR helps companies define and improve
their approach to performance metrics, developing KPIs best tailored to the
specific context of the company and setting the foundation so that they can be
successfully introduced within the company. KMR works with clients to help them
effectively: monitor performance according to the metrics, employ the data to
demonstrate progress, benchmark performance against the broader industry, and
identify areas for improvement.
|
| |
|
|
|
|
|
| |
KMR collects data (e.g., cycle time,
cost, quality) on the CROs a client has recently used or from CRO clients
themselves. KMR then evaluates the CRO performance against the industry
standard, helping clients understand various CROs strengths and weaknesses and
better select and manage CROs. For CRO clients, it highlights areas for
improvement and gives a comparison with other CROs.
|
| |
|
| |
KMR provides a detailed analysis of the individual
CROs used by a pharmaceutical company, comparing the CROs against: the
company's internal performance, the performance achieved by CROs in general,
the best in class CRO, pharmaceutical companies in general, and the best in
class pharmaceutical company.
|
| |
| |
|
| |
|
| |
|
-
Forums/Common Interest Groups
|
| |
KMR has over 10 years of experience
facilitating forums for the discussion of benchmarking information relating to
pharmaceuticals. This facilitation is critical in achieving agreed objectives,
definitions and common understanding of the results. For example, KMR recently
presented data on R&D trends and investment, pharmacogenetics, and clinical
resources. The conferences were specifically designed to allow KMR to present
data to selected representatives within the pharmaceutical industry. Topics
covered by recent forums include: Biologics, Pharmacogenetics, Preclinical
Development, Safety Reporting Processes, R&D General Metrics, Portfolio
Management, Project Management, Information Technology.
|
|